Carregant...
Low‐dose IL‐2 induces CD56(bright )NK regulation of T cells via NKp44 and NKp46
Low‐dose interleukin (IL)‐2 has shown clinical benefits in patients with autoimmune and inflammatory diseases. Both regulatory T cells (T(regs)) and natural killer (NK) cells are increased in response to low‐dose IL‐2 immunotherapy. The role of regulatory T cells in autoimmune diseases has been exte...
Guardat en:
| Publicat a: | Clin Exp Immunol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7232012/ https://ncbi.nlm.nih.gov/pubmed/31989589 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13422 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|